Highlights Eli Lilly and Company

Stocks

LLY

US5324571083

Pharmaceuticals

Market Closed - NYSE Other stock markets 00:02:19 11/07/2026 +04			After hours 04:00:00
1,188.58 ^USD	-2.33%		1,191.00	+0.20%

07-11	Health Care Down on Rotation Back to Tech - Health Care Roundup	DJ
07-10	Biopharma Pricing Power Seen as Key Swing Factor for Q2 Earnings, BofA Says	MT

Highlights

07-09	Truist Securities Expects Q2 Beat from Eli Lilly; Price Target, Estimates Up	MT
07-08	Eli Lilly Could Deliver 'Beat-and-Raise' Quarter, Truist Says	MT
07-08	Eli Lilly Expected to Beat Q2 Revenue Forecasts on Weight-Loss Drugs, RBC Says	MT
07-08	RBC Lifts Eli Lilly Price Target on Expected 'Strong' Q2 Performance of Obesity Drugs	MT
07-07	Eli Lilly Says Health Canada Approves Mounjaro for Children With Type 2 Diabetes	MT
07-06	Eli Lilly Products to be Sold, Distributed by DKSH in Hong Kong, Macau	MT
06-30	Hybio's generic weight-loss drug set for FDA review	RE
06-30	Eli Lilly, Innovent Biologics Sign China Distribution Agreement for Verzenios	MT
06-29	Lilly, Regeneron selected for US program to review new manufacturing plants faster	RE
06-29	FDA selects Lilly, Regeneron for program to speed up review of new manufacturing facilities, CNBC reports	RE
06-29	Eli Lilly, Abu Dhabi's Health Department Enter MoU to Manage Obesity, Alzheimer's Disease	MT
06-26	Eli Lilly And Company Receives Positive Opinion From CHMP For Jaypirca For Treatment Of Adults With Chronic Lymphocytic Leukemia Across All Lines Of Therapy	CI
06-26	Eli Lilly's Blood Cancer Therapy Recommended for EU Approval	MT
06-26	Eli Lilly's Blood Cancer Therapy Recommended for EU Approval	MT
06-26	Eli Lilly Unit's Once-weekly Insulin Recommended for EU Approval	MT
06-24	Eli Lilly Completes Acquisition of Centessa Pharmaceuticals	MT
06-24	Abbisko Cayman Limited and Eli Lilly and Company Deepen R&D Collaboration	CI
06-24	Eli Lilly Sees Weight-loss Pill Approval in China by 2026-end	MT
06-24	Eli Lilly Signs Strategic Research, License Deal With Abbisko Therapeutics	MT
06-23	Eli Lilly and Company entered into asset sale agreement to acquire Certain Assets from Sangamo Therapeutics, Inc..	CI
06-23	Eli Lilly, Astellas Enter Into Asset Sale Agreements With Sangamo Therapeutics	MT
06-23	UK High Court Approves Lilly's $7.8 Billion Acquisition of Centessa	MT
06-22	Eli Lilly Reports Long-Term Data for Lebrikizumab in Atopic Dermatitis	CI
06-22	Eli Lilly Keeps Quarterly Dividend at $1.73 a Share, Payable Sept. 10 to Holders of Record Aug. 14	MT
06-22	Eli Lilly and Company Declares Dividend for the Third Quarter of 2026, Payable on September 10, 2026	CI